The global dysmenorrhea treatment market was valued at US$ 5,937.8 million by the end of the year 2022. In the current year 2023, the global demand for dysmenorrhea treatment services is estimated to be valued at US$ 6,324.5 million. A year-on-year growth rate of 8.3% is expected for the market during the forecast period from 2023 to 2033. By following this significant CAGR, the global market value is projected to reach US$ 13,906.5 million by 2033.
Dysmenorrhea is a clinical term for menstrual cramps in which a woman experiences severe pain or cramps in her abdominal area that may spread to her lower legs and back. Most women begin suffering from dysmenorrhea throughout adolescence, generally after four to five years of the first menstrual cycle.
Prostaglandins are substances that are produced in the uterine lining during menstruation. These prostaglandins generate uterine muscular spasms, which cause discomfort and reduce blood supply and oxygen to the uterus. Menstrual problems can be caused by a wide range of underlying conditions.
Lifestyle modifications, changes in the environment, and food preferences all have a significant influence on human bodies, which has also raised the occurrence of dysmenorrhea among women. Also, the increased frequency of dysmenorrhea has led to increased health consciousness among women to treat the illness, which is projected to drive market growth.
The increased consumer awareness of dysmenorrhea therapy, as well as the low cost of over-the-counter medications, are two important factors driving growth in the market. Moreover, the increased usage of drugs to relieve pain during menstruation, in turn, drives the growth of the worldwide dysmenorrhea treatment market.
The increase in technological improvement in the healthcare industry is likely to fuel the growth of the market throughout the forecast period. However, long-term treatment’s side effects and issues, the high morbidity of menstrual cramps leading to inadequate treatments, and traditional family values are expected to stymie the growth of the dysmenorrhea treatment industry.
| Report Attributes or Data Points | Details |
|---|---|
| Global Dysmenorrhea Treatment Market Valuation in 2022 | US$ 5,937.8 million |
| Estimated Global Market Share in 2023 | US$ 6,324.5 million |
| Forecasted Global Market Size by 2033 | US$ 13,906.5 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 8.3% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 5.4% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The growing healthcare spending, which aids in the improvement of infrastructure, is a crucial element driving the development rate of the market. Furthermore, numerous government organizations intend to improve healthcare infrastructure by boosting financing, which might have an impact on market dynamics.
People's changing lifestyles are expected to have an impact on market dynamics throughout the projected period from 2023 to 2033. Changing lifestyles, along with bad eating habits, have a significant influence on the human body. As a result, the prevalence of dysmenorrhea/menstrual cramps among women has increased. Climate factors are also thought to increase the likelihood of menstruation cramps.
A growing number of government measures to raise awareness and increase the aging population might result in market expansion. Additionally, increased disposable income and urbanization are estimated to boost the market's growth rate.
The high cost of care, on the other hand, is likely to impede the growth rate of the overall market during the forecast period between 2023 and 2033. The global market could face challenges due to a lack of healthcare infrastructure in emerging nations and a stringent regulatory environment. Furthermore, a lack of public awareness and inadequate reimbursement policies may hinder market expansion during the projection period from 2023 to 2033.
Challenges related to long-term care and other side effects and issues, the high morbidity of menstrual cramps due to insufficient treatments, and traditional family values are expected to stymie the growth of the global market.
Principal Consultant
The endometriosis segment is expected to gain a global market share of 35% during the forecast period. Furthermore, the rising prevalence of endometriosis is projected to drive the global market forward.
The global prevalence of disorders such as endometriosis, the primary cause of secondary dysmenorrhea, is also increasing. Endometriosis affects an estimated 1 in 10 women throughout their reproductive years, or around 176 million people globally, according to an article titled Understanding Endometriosis - the Basics published in July 2021. This factor is predicted to have a substantial influence on market growth. As a result of the aforementioned causes, the non-steroidal anti-inflammatory medicines category is predicted to considerably contribute to market growth.
| Category | By Disease Type |
|---|---|
| Top Segment | Primary Dysmenorrhea |
| Market Share in Percentage | 63.4% |
| Category | By Therapeutic Class |
|---|---|
| Top Segment | Non-steroidal Anti-inflammatory drugs (NSAIDs) |
| Market Share in Percentage | 35.4% |
In terms of market share and revenue, North America’s market is expected to be the dominant market for dysmenorrhea treatments during the projection period from 2023 to 2033. The analysts at Future Market Insights observed that in 2022, the market of dysmenorrhea treatment in North America acquired a global market share of 37.2%. This will maintain its supremacy throughout the projected period.
Technological innovation and increased healthcare spending is going to propel the market's growth rate in this area even fast. Furthermore, the presence of significant key competitors and rising pharmaceutical consumption are a few other factors that are estimated to fuel the market's development rate in this area notably
Furthermore, growth in research and development procedures for generating new pharmaceuticals and assessing the potential of existing therapies may improve the market under consideration. For example,
A January 2019 research titled Continuous vs. cyclic combined hormonal contraceptives for the treatment of dysmenorrhea: a comprehensive review found that flexible/extended combined hormonal contraceptives (CHC) culminated in four few days of dysmenorrhea than the cyclic regimen. Such research projects are likely to considerably contribute to the market's growth.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 37.2% |
| Europe | 24.2% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By 2022, Europe held around 24.2% of the global market share. This region is expected to be one of the significantly growing markets for dysmenorrhea treatment during the forecast period.
The increasing number of research and development activities is driving the market's expansion further. This could give advantageous chances for the expansion of the dysmenorrhea treatment market. Also, leading corporations are investing in research and development. This brings up a lot of market opportunities.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| The United States | 29.5% |
| Germany | 5.1% |
| Japan | 5.1% |
The Asia Pacific region is expected to develop at a significant CAGR during the forecast period. This is owing to a rise in the prevalence of dysmenorrhea and menstrual health issues in this region for treatment. Furthermore, the expansion of healthcare infrastructure and growing government efforts might accelerate the market's growth rate in this area.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| The United Kingdom | 6% |
| China | 11% |
| India | 9% |
| Australia | 5.3% |
The key players of this market include Novartis Pharmaceuticals Corporation, Merck, Inc., Bayer Schering Pharma AG, Vanita Therapeutics, Nua, Cora, Alvogen, Pfizer, Inc., Roche Laboratories, Taj Pharmaceuticals, Ltd., Sanofi, and Terramedic, Inc.
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 8.2% from 2023 to 2033 |
| Market value in 2023 | US$ 6,324.5 million |
| Market value in 2033 | US$ 13,906.5 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | US$ million for Value |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization Scope | Available on Request |
The market is valued at US$ 6,324.5 million in 2023.
A CAGR of 11% is predicted for China by 2033.
The market is projected to reach US$ 13,906.5 million in 2033.
The market is occupied by primary dysmenorrhea in disease type with a share of 63.4%.
The market was valued at US$ 5,937.8 million in 2022.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diseases 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Diseases, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diseases, 2023 to 2033 5.3.1. Primary Dysmenorrhea 5.3.2. Secondary Dysmenorrhea 5.3.3. Endometriosis 5.3.4. Adenomyosis 5.3.5. Uterine Myomas 5.3.6. Endometrial Polyps 5.3.7. Cervical Stenosis 5.3.8. Obstructive Malformations Of Genital Tract 5.4. Y-o-Y Growth Trend Analysis By Diseases, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Diseases, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Class 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Class, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Class, 2023 to 2033 6.3.1. Non-Hormonal Medical Treatment 6.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) 6.3.3. Non-Selective Nsaids 6.3.4. Cox-2 Inhibitors 6.3.5. Transdermal Glyceryl Trinitrate 6.3.6. Over-The-Counter (Otc) Medications 6.3.7. Hormonal Medicine Treatment 6.3.8. Combined Oral Contraceptive 6.3.9. Progestin Regimens 6.3.10. Surgical Options 6.3.11. Laparoscopy 6.3.12. Hysterectomy 6.4. Y-o-Y Growth Trend Analysis By Therapeutic Class, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Therapeutic Class, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Diseases 8.2.3. By Therapeutic Class 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Diseases 8.3.3. By Therapeutic Class 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Diseases 9.2.3. By Therapeutic Class 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Diseases 9.3.3. By Therapeutic Class 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Diseases 10.2.3. By Therapeutic Class 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Diseases 10.3.3. By Therapeutic Class 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Diseases 11.2.3. By Therapeutic Class 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Diseases 11.3.3. By Therapeutic Class 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Diseases 12.2.3. By Therapeutic Class 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Diseases 12.3.3. By Therapeutic Class 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Diseases 13.2.3. By Therapeutic Class 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Diseases 13.3.3. By Therapeutic Class 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Diseases 14.2.3. By Therapeutic Class 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Diseases 14.3.3. By Therapeutic Class 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Diseases 15.1.2.2. By Therapeutic Class 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Diseases 15.2.2.2. By Therapeutic Class 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Diseases 15.3.2.2. By Therapeutic Class 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Diseases 15.4.2.2. By Therapeutic Class 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Diseases 15.5.2.2. By Therapeutic Class 15.6. UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Diseases 15.6.2.2. By Therapeutic Class 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Diseases 15.7.2.2. By Therapeutic Class 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Diseases 15.8.2.2. By Therapeutic Class 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Diseases 15.9.2.2. By Therapeutic Class 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Diseases 15.10.2.2. By Therapeutic Class 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Diseases 15.11.2.2. By Therapeutic Class 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Diseases 15.12.2.2. By Therapeutic Class 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Diseases 15.13.2.2. By Therapeutic Class 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Diseases 15.14.2.2. By Therapeutic Class 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Diseases 15.15.2.2. By Therapeutic Class 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Diseases 15.16.2.2. By Therapeutic Class 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Diseases 15.17.2.2. By Therapeutic Class 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Diseases 15.18.2.2. By Therapeutic Class 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Diseases 15.19.2.2. By Therapeutic Class 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Diseases 15.20.2.2. By Therapeutic Class 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Diseases 15.21.2.2. By Therapeutic Class 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Diseases 15.22.2.2. By Therapeutic Class 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Diseases 15.23.2.2. By Therapeutic Class 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Diseases 16.3.3. By Therapeutic Class 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Novartis Pharmaceuticals Corporation, 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Merck, Inc., 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Bayer Schering Pharma AG, 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Vanita Therapeutics, 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Alvogen, 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Pfizer, Inc., 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Nua 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Cora 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Roche Laboratories, 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Taj Pharmaceuticals, Ltd., 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Dysmenorrhea Treatment Market
